By: ABRS- Academic Team
Introduction
A clinical trial no longer has to revolve around a single physical site to generate meaningful evidence. Participant interactions may take place remotely, data may come from digital technologies or routine healthcare settings, and some study activities may be distributed across a wider network of professionals and locations. That shift is precisely the kind of operating environment addressed in ICH E6(R3) Annex 2, which extends the application of Good Clinical Practice principles to trials that incorporate decentralized elements, pragmatic approaches, and real-world data.
For clinical operations teams, the immediate question is not simply what Annex 2 says, but what its direction may mean for the way studies are planned and supported. The document points toward a model in which established GCP principles must remain applicable even when activities, data sources, technologies, and responsibilities are more distributed. That raises practical questions around coordination, oversight, data suitability, and the clarity of responsibilities across the trial ecosystem.
There is also an important regulatory distinction to keep in view. ICH reached Step 4 for Annex 2 in June 2026, and the European Medicines Agency indicates that the guideline is scheduled to become effective in the European Union on 15 January 2027. In contrast, the FDA currently presents E6(R3) Annex 2 as draft guidance and not for implementation. For that reason, Annex 2 should not yet be treated as a uniform global requirement.
The value of reviewing it now is to understand the operational direction it signals. Rather than presenting these considerations as settled requirements across every jurisdiction, this blog looks at what clinical teams can reasonably begin to examine based on the current text: how responsibilities may need to be coordinated across distributed activities, how different data sources can remain fit for purpose, and how oversight can remain effective as trial models become less dependent on a traditional site-centered structure.
Applying GCP Across Evolving Trial Model
Annex 2 does not introduce a separate version of Good Clinical Practice for decentralized, pragmatic, or real-world data–enabled trials. Instead, it is intended to extend the application of the existing E6(R3) principles to study designs and data sources that may operate differently from a conventional site-centered trial. The ICH E6(R3) Annex 2 specifically addresses decentralized clinical trials, pragmatic clinical trials, and trials incorporating real-world data, while emphasizing that the Annex should be read together with the overarching Principles and Annex 1. European Medicines Agency
One theme that runs through the current text is proportionality. Different trial designs may involve different levels of complexity, risk, and reliance on routine healthcare processes or technologies. Rather than prescribing the same operational approach for every study, E6(R3) encourages approaches that are fit for their intended purpose and proportionate to the risks that could affect participant protection or the reliability of trial results. The EMA overview of ICH E6(R3) also highlights quality by design and proportionate, risk-based approaches as underlying concepts of the revised guideline. European Medicines Agency
From an operational perspective, this suggests that adopting a decentralized element or using real-world data should not be viewed simply as adding a new technology or data source to an existing protocol. Teams may need to consider whether the selected approach is appropriate for the trial objective, what risks it introduces, how responsibilities are distributed, and whether participants and investigators can realistically work within the proposed model. These are operational considerations derived from the direction of Annex 2 rather than universal implementation requirements across all jurisdictions.
The current Annex therefore points toward flexibility, but not flexibility without structure. As study activities move beyond traditional site boundaries, the underlying expectations around participant protection, reliable results, appropriate oversight, and clearly defined responsibilities remain relevant. For clinical operations teams, the practical question is how those principles can be preserved when the way a trial is conducted becomes more distributed, pragmatic, or dependent on data generated outside traditional clinical trial processes.
Distributed Trial Activities Require Clear Operational Coordination
When trial activities extend beyond the traditional investigator site, responsibility does not disappear; it becomes more distributed. The current ICH E6(R3) Annex 2 describes situations in which healthcare professionals may perform trial-related activities that are part of usual clinical practice. It also indicates that the protocol should identify those activities and that appropriate arrangements should exist for making relevant information and records available to the investigator. ICH Database
This distinction becomes especially important when an activity requires specific knowledge of the protocol, investigator’s brochure, or other trial documents. Annex 2 indicates that activities requiring that level of trial-specific knowledge should be performed by appropriately trained individuals under suitable investigator oversight. By contrast, some routine healthcare activities may be performed by local healthcare professionals when the necessary arrangements for information sharing, record retention, privacy, and data integrity are in place. ICH Database
The operational implication is that decentralization may create more interfaces that need to be coordinated. A participant could interact with the investigator site, a local healthcare professional, home nursing services, digital health technologies, or other service providers over the course of the same study. Clinical teams may therefore need to think carefully about where information originates, how quickly it reaches the investigator, and how responsibilities are documented across those different points of contact. This is particularly relevant for safety information, since Annex 2 states that information generated through sources such as home nursing, remote visits, or digital health technologies should reach the investigator in a way that supports participant-care decisions. ICH E6(R3) Annex 2 ICH Database
Similar operational considerations can already be seen in FDA’s final 2024 guidance on Conducting Clinical Trials With Decentralized Elements. That guidance discusses the use of telehealth, in-home visits, local healthcare providers, and digital health technologies, while distinguishing routine clinical activities from research-specific activities that require trained trial personnel. This FDA guidance is separate from the current U.S. draft status of E6(R3) Annex 2, but it provides useful context for how distributed trial activities are already being approached operationally in the United States. U.S. Food and Drug Administration
For clinical operations teams, the emerging message is not that every decentralized study needs a more complicated operating model. Rather, distributed activities may require greater clarity about who performs each task, who retains oversight, where records are maintained, and how information moves back to the people responsible for participant safety and trial decisions. These are areas that teams can begin examining now, while remaining mindful that the implementation status of Annex 2 continues to vary by jurisdiction.
Data Sources Need to Remain Fit for Purpose
Using real-world data does not automatically make a data source suitable for a clinical trial. The question is whether the information can support the study objective and the decisions the trial is intended to inform. The EMA overview of ICH E6(R3) explains that Annex 2 addresses trials incorporating real-world data sources with the broader objective of ensuring that trial designs and data sources are fit for their intended purpose. That framing is important: the emphasis is not on expanding the number of available data sources, but on understanding whether a particular source is appropriate for the way it will be used. European Medicines Agency
For clinical operations teams, this may require looking beyond where the data originate. Electronic health records, medical claims, registries, digital health technologies, and other routinely collected information may differ substantially in how data are captured, structured, updated, and maintained. FDA’s final guidance on assessing electronic health records and medical claims data for regulatory decision-making provides complementary context by outlining considerations for sponsors proposing to use these sources in studies supporting regulatory decisions related to effectiveness or safety. U.S. Food and Drug Administration
This creates an operational need to understand the data source before relying on it. Teams may need to consider whether relevant variables are available, how consistently they are collected, what information may be missing, and whether the origin and transformation of the data can be adequately understood. These considerations should not be interpreted as a new universal checklist derived from Annex 2. Rather, they illustrate the type of questions that may become relevant when applying the Annex’s fit-for-purpose principle to real-world data. FDA’s broader guidance on the use of RWD and RWE in regulatory decision-making also reflects the importance of evaluating real-world evidence within the context of its intended regulatory use. U.S. Food and Drug Administration
For clinical operations, the practical implication is that data strategy may need to become part of operational planning earlier in the study lifecycle. When information is generated outside traditional trial processes, coordination among clinical, data management, biostatistics, technology, and regulatory functions may help teams understand how the source will be accessed, interpreted, transferred, and incorporated into the trial. Based on the current direction of Annex 2, fit for purpose is therefore not only a data-management consideration; it may also influence how responsibilities, systems, and oversight are organized around the evidence the study is designed to generate.
Conclusion:
ICH E6(R3) Annex 2 signals a broader shift in how Good Clinical Practice principles may be applied when trials extend beyond conventional site-based models. Decentralized activities, pragmatic approaches, and real-world data can introduce greater flexibility, but they also create new operational interfaces that clinical teams need to understand. The current ICH E6(R3) Annex 2 points toward maintaining the same fundamental focus on participant protection and reliable trial results while adapting processes to the design, risks, technologies, and data sources involved.
For clinical operations, preparation does not necessarily mean redesigning existing processes before regulatory implementation is established in each jurisdiction. A more practical starting point is to examine where responsibilities may become distributed, how information will move between investigators and other trial participants, whether new data sources are suitable for their intended use, and how oversight can remain proportionate as the operating model changes.
That distinction is especially important because Annex 2 does not yet have the same regulatory status everywhere. The European Medicines Agency indicates that Annex 2 is scheduled to become effective in the European Union on 15 January 2027, while the FDA currently lists its E6(R3) Annex 2 guidance as draft and not for implementation. Clinical teams should therefore distinguish between understanding the direction of the guidance and treating its provisions as requirements that already apply uniformly across markets.
The opportunity at this stage is to use the available guidance as a lens for operational readiness. Reviewing responsibilities, data pathways, technologies, and oversight arrangements now can help teams identify where additional clarity may be needed as regulatory adoption progresses. For global clinical research organizations, the challenge will be to preserve consistent GCP principles while adapting execution to different trial designs, data environments, and jurisdiction-specific expectations.
